Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Black History Month 2022
Past motivations: This piece focusses on people’s stories and their past motivations in life that have led them to where they are today.
Overcoming hurdles: This piece considers the struggles people have faced working within STEM whilst building their careers and how they have overcome these hurdles.
International Day of Women and Girls in Science: This piece focusses on celebrating the achievements of Black women who work within STEM, to highlight International Day of Women and Girls in Science 2022.
Helpful resources: This piece highlights the advice our experts have received during their careers and the resources they have found the most helpful.
Achievements: This piece examines the achievements our experts have attained in their careers whilst working within the STEM industry.
Advice: The final piece highlights our experts’ advice for those who are in the early stages of their careers.
-
Gene therapy – affordability, access and reimbursement
Brian Huber, Vice President, Drug Development Services, considers the affordability, access and reimbursement challenges within the gene therapy market.
-
How CRO venture capital relationships can help biotech fundraising
This article considers how partnering with a CRO can help emerging biotechs to secure funding.
-
JPM 2022: Decentralised trials, broader service offerings and novel drugs key trends in the CRO space
In this snapshot from the J.P. Morgan Healthcare Conference, Steve Cutler comments on ICON’s success in decentralised trials and therapeutic technologies such as mRNA and checkpoint inhibitors.
-
ICON issues financial guidance for 2022 as the CRO giant eyes spike in revenue growth
This article discusses ICON’s forecast revenues for 2022 and includes a statement from Steve Cutler on ICON’s successes from 2021.
-
The personalised medicine paradigm
Cindy Spittle shares insights on the growth of molecular diagnostic testing in clinical trials.
-
Sharing clinical trial results with paediatric participants
Kirsten Sherman Cervati contributes to this media article which discusses the considerations for returning results to paediatric participants.
-
In-Home Services: A patient-centric approach to improving recruitment and retention in clinical trials
Advances in wearables, telemedicine and remote monitoring technology along with the convenience of in-home visits were bound to make decentralised and hybrid clinical trials standard with enough time. However, the COVID-19 pandemic accelerated their adoption and now, even with the hope that the pandemic will soon be behind us, hybrid and decentralised models are poised to become viable solutions in clinical trial design because of their inherent agility, inclusivity and most importantly, patient centricity.
-
Capture, curate, consume: The three Cs of managing data in decentralised and hybrid clinical trials
Emily Mitchell, Executive Director, Decentralised Clinical Trials Operations and Christina Dinger, Director, Decentralised Clinical Trials Operations, run through some of the most important elements of collating and organising data during clinical trials.
This article was taken from Pharmafocus December 2021, pages 16-17. Samedan Ltd.
-
Combating antimicrobial resistance
Shelley McLendon, Vice President, Vaccines and Infectious Disease, discusses the use of novel diagnostics to help monitor for AMR outbreaks and reduce the overuse and misuse of antimicrobials.
